Cardiol Therapeutics Inc. (NASDAQ: CRDL) Stock Competitors & Peer Comparison
See CRDL's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CRDL and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CRDL | $2.17 | +0.93% | 250.1M | -8.65 | -$0.25 | N/A |
| TAK | $18.43 | +1.10% | 58.7B | 13.26 | $1.39 | +3.42% |
| HLN | $9.91 | -1.59% | 43.7B | 18.50 | $0.54 | +1.25% |
| TEVA | $37.49 | +3.59% | 43.6B | 12.79 | $2.93 | N/A |
| ZTS | $76.17 | -1.40% | 31.9B | 11.57 | $6.58 | +2.73% |
| VTRS | $17.09 | +2.77% | 19.9B | 6.78 | $2.52 | +2.81% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $24.68 | +3.22% | 12.3B | 23.28 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $12.17 | +0.00% | 10.1B | 19.94 | $0.61 | +0.69% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
CRDL vs TAK Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, TAK has a market cap of 58.7B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while TAK trades at $18.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas TAK's P/E ratio is 13.26. In terms of profitability, CRDL's ROE is -1.94%, compared to TAK's ROE of +0.02%. Regarding short-term risk, CRDL is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check TAK's competition here
Haleon plc (NYSE: HLN)
CRDL vs HLN Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, HLN has a market cap of 43.7B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while HLN trades at $9.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas HLN's P/E ratio is 18.50. In terms of profitability, CRDL's ROE is -1.94%, compared to HLN's ROE of +0.17%. Regarding short-term risk, CRDL is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
CRDL vs TEVA Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, TEVA has a market cap of 43.6B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while TEVA trades at $37.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas TEVA's P/E ratio is 12.79. In terms of profitability, CRDL's ROE is -1.94%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, CRDL is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check TEVA's competition here
Zoetis Inc. (NYSE: ZTS)
CRDL vs ZTS Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, ZTS has a market cap of 31.9B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while ZTS trades at $76.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas ZTS's P/E ratio is 11.57. In terms of profitability, CRDL's ROE is -1.94%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, CRDL is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
CRDL vs VTRS Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, VTRS has a market cap of 19.9B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while VTRS trades at $17.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas VTRS's P/E ratio is 6.78. In terms of profitability, CRDL's ROE is -1.94%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, CRDL is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
CRDL vs ITCI Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas ITCI's P/E ratio is -180.64. In terms of profitability, CRDL's ROE is -1.94%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, CRDL is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
CRDL vs ELAN Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, ELAN has a market cap of 12.3B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while ELAN trades at $24.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas ELAN's P/E ratio is 23.28. In terms of profitability, CRDL's ROE is -1.94%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, CRDL is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
CRDL vs CTLT Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas CTLT's P/E ratio is -27.84. In terms of profitability, CRDL's ROE is -1.94%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, CRDL is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
CRDL vs RDY Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, RDY has a market cap of 10.1B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while RDY trades at $12.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas RDY's P/E ratio is 19.94. In terms of profitability, CRDL's ROE is -1.94%, compared to RDY's ROE of +0.09%. Regarding short-term risk, CRDL is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
CRDL vs ALKS Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, ALKS has a market cap of 8B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while ALKS trades at $47.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas ALKS's P/E ratio is 50.23. In terms of profitability, CRDL's ROE is -1.94%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, CRDL is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
CRDL vs LNTH Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while LNTH trades at $100.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas LNTH's P/E ratio is 16.94. In terms of profitability, CRDL's ROE is -1.94%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, CRDL is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
CRDL vs AMRX Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, AMRX has a market cap of 5.8B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while AMRX trades at $18.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas AMRX's P/E ratio is 20.07. In terms of profitability, CRDL's ROE is -1.94%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, CRDL is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
CRDL vs INDV Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, INDV has a market cap of 4.4B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while INDV trades at $35.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas INDV's P/E ratio is 9.60. In terms of profitability, CRDL's ROE is -1.94%, compared to INDV's ROE of -2.16%. Regarding short-term risk, CRDL is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check INDV's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
CRDL vs RGC Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, RGC has a market cap of 3.1B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while RGC trades at $6.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas RGC's P/E ratio is -444.37. In terms of profitability, CRDL's ROE is -1.94%, compared to RGC's ROE of -2.32%. Regarding short-term risk, CRDL is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check RGC's competition here
Alvotech (NASDAQ: ALVOW)
CRDL vs ALVOW Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, ALVOW has a market cap of 3B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while ALVOW trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas ALVOW's P/E ratio is 47.36. In terms of profitability, CRDL's ROE is -1.94%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, CRDL is less volatile compared to ALVOW. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check ALVOW's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
CRDL vs SUPN Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, SUPN has a market cap of 2.6B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while SUPN trades at $44.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas SUPN's P/E ratio is 14.39. In terms of profitability, CRDL's ROE is -1.94%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, CRDL is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check SUPN's competition here
Bausch Health Companies Inc. (NYSE: BHC)
CRDL vs BHC Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, BHC has a market cap of 2.6B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while BHC trades at $6.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas BHC's P/E ratio is 1.74. In terms of profitability, CRDL's ROE is -1.94%, compared to BHC's ROE of +0.89%. Regarding short-term risk, CRDL is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
CRDL vs DCPH Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas DCPH's P/E ratio is -11.58. In terms of profitability, CRDL's ROE is -1.94%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, CRDL is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
CRDL vs AVDL Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, CRDL's ROE is -1.94%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, CRDL is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check AVDL's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
CRDL vs HCM Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while HCM trades at $12.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas HCM's P/E ratio is 4.51. In terms of profitability, CRDL's ROE is -1.94%, compared to HCM's ROE of +0.01%. Regarding short-term risk, CRDL is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check HCM's competition here
Perrigo Company plc (NYSE: PRGO)
CRDL vs PRGO Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, PRGO has a market cap of 2B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while PRGO trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas PRGO's P/E ratio is 5.79. In terms of profitability, CRDL's ROE is -1.94%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, CRDL is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check PRGO's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
CRDL vs TRLV Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while TRLV trades at $11.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas TRLV's P/E ratio is -4.76. In terms of profitability, CRDL's ROE is -1.94%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, CRDL is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check TRLV's competition here
Embecta Corp. (NASDAQ: EMBCV)
CRDL vs EMBCV Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas EMBCV's P/E ratio is N/A. In terms of profitability, CRDL's ROE is -1.94%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, CRDL is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
CRDL vs DVAX Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas DVAX's P/E ratio is -41.89. In terms of profitability, CRDL's ROE is -1.94%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, CRDL is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
CRDL vs ALVO Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while ALVO trades at $5.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas ALVO's P/E ratio is -15.71. In terms of profitability, CRDL's ROE is -1.94%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, CRDL is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check ALVO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
CRDL vs ETON Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, ETON has a market cap of 1.7B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while ETON trades at $61.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas ETON's P/E ratio is 134.70. In terms of profitability, CRDL's ROE is -1.94%, compared to ETON's ROE of +0.40%. Regarding short-term risk, CRDL is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check ETON's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
CRDL vs ANIP Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while ANIP trades at $73.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas ANIP's P/E ratio is 8.89. In terms of profitability, CRDL's ROE is -1.94%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, CRDL is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check ANIP's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
CRDL vs PAHC Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while PAHC trades at $39.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas PAHC's P/E ratio is 13.62. In terms of profitability, CRDL's ROE is -1.94%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, CRDL is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check PAHC's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
CRDL vs TARO Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas TARO's P/E ratio is 30.05. In terms of profitability, CRDL's ROE is -1.94%, compared to TARO's ROE of +0.03%. Regarding short-term risk, CRDL is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
CRDL vs HROW Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while HROW trades at $39.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas HROW's P/E ratio is -39.44. In terms of profitability, CRDL's ROE is -1.94%, compared to HROW's ROE of -1.04%. Regarding short-term risk, CRDL is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check HROW's competition here
Cronos Group Inc. (NASDAQ: CRON)
CRDL vs CRON Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while CRON trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas CRON's P/E ratio is 30.77. In terms of profitability, CRDL's ROE is -1.94%, compared to CRON's ROE of +0.06%. Regarding short-term risk, CRDL is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
CRDL vs AMPH Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, AMPH has a market cap of 1B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while AMPH trades at $23.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas AMPH's P/E ratio is 8.10. In terms of profitability, CRDL's ROE is -1.94%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, CRDL is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check AMPH's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
CRDL vs PCRX Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while PCRX trades at $26.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas PCRX's P/E ratio is 10.22. In terms of profitability, CRDL's ROE is -1.94%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, CRDL is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
CRDL vs PETQ Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas PETQ's P/E ratio is 83.73. In terms of profitability, CRDL's ROE is -1.94%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, CRDL is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
CRDL vs COLL Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, COLL has a market cap of 788.1M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while COLL trades at $24.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas COLL's P/E ratio is 3.05. In terms of profitability, CRDL's ROE is -1.94%, compared to COLL's ROE of +0.16%. Regarding short-term risk, CRDL is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
CRDL vs IRWD Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, IRWD has a market cap of 725.9M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while IRWD trades at $4.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas IRWD's P/E ratio is 5.65. In terms of profitability, CRDL's ROE is -1.94%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, CRDL is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check IRWD's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
CRDL vs AQST Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, AQST has a market cap of 675M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while AQST trades at $5.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas AQST's P/E ratio is -8.28. In terms of profitability, CRDL's ROE is -1.94%, compared to AQST's ROE of +2.44%. Regarding short-term risk, CRDL is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check AQST's competition here
Evotec SE (NASDAQ: EVO)
CRDL vs EVO Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, EVO has a market cap of 675M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while EVO trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas EVO's P/E ratio is -2.68. In terms of profitability, CRDL's ROE is -1.94%, compared to EVO's ROE of -0.27%. Regarding short-term risk, CRDL is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check EVO's competition here
Glass House Brands Inc (NYSE: GLAS)
CRDL vs GLAS Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, GLAS has a market cap of 661.2M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while GLAS trades at $8.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas GLAS's P/E ratio is -15.26. In terms of profitability, CRDL's ROE is -1.94%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, CRDL is more volatile compared to GLAS. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check GLAS's competition here
Evolus, Inc. (NASDAQ: EOLS)
CRDL vs EOLS Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, EOLS has a market cap of 596.6M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while EOLS trades at $9.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas EOLS's P/E ratio is -28.69. In terms of profitability, CRDL's ROE is -1.94%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, CRDL is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check EOLS's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
CRDL vs BDSI Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas BDSI's P/E ratio is 6.82. In terms of profitability, CRDL's ROE is -1.94%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, CRDL is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
CRDL vs TLRY Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, TLRY has a market cap of 505.5M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while TLRY trades at $4.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas TLRY's P/E ratio is -4.17. In terms of profitability, CRDL's ROE is -1.94%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, CRDL is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
CRDL vs KMDA Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, KMDA has a market cap of 484.6M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while KMDA trades at $8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas KMDA's P/E ratio is 22.11. In terms of profitability, CRDL's ROE is -1.94%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, CRDL is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
CRDL vs CGC Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, CGC has a market cap of 408.7M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while CGC trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas CGC's P/E ratio is -0.58. In terms of profitability, CRDL's ROE is -1.94%, compared to CGC's ROE of -0.33%. Regarding short-term risk, CRDL is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
CRDL vs TKNO Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, TKNO has a market cap of 398.4M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while TKNO trades at $7.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas TKNO's P/E ratio is -23.97. In terms of profitability, CRDL's ROE is -1.94%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, CRDL is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check TKNO's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
CRDL vs EBS Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, EBS has a market cap of 333.6M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while EBS trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas EBS's P/E ratio is 4.49. In terms of profitability, CRDL's ROE is -1.94%, compared to EBS's ROE of -0.36%. Regarding short-term risk, CRDL is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
CRDL vs ALIM Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas ALIM's P/E ratio is 5.28. In terms of profitability, CRDL's ROE is -1.94%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, CRDL is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
CRDL vs LNDC Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas LNDC's P/E ratio is -4.04. In terms of profitability, CRDL's ROE is -1.94%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, CRDL is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
CRDL vs ACB Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, ACB has a market cap of 249.6M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while ACB trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas ACB's P/E ratio is -8.23. In terms of profitability, CRDL's ROE is -1.94%, compared to ACB's ROE of -0.21%. Regarding short-term risk, CRDL is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check ACB's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
CRDL vs SIGA Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, SIGA has a market cap of 230.2M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while SIGA trades at $3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas SIGA's P/E ratio is 11.89. In terms of profitability, CRDL's ROE is -1.94%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, CRDL is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check SIGA's competition here
Shineco, Inc. (NASDAQ: TYHT)
CRDL vs TYHT Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas TYHT's P/E ratio is -1.61. In terms of profitability, CRDL's ROE is -1.94%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, CRDL is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check TYHT's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
CRDL vs ORGO Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, ORGO has a market cap of 214.9M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while ORGO trades at $1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas ORGO's P/E ratio is 55.67. In terms of profitability, CRDL's ROE is -1.94%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, CRDL is more volatile compared to ORGO. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check ORGO's competition here
Journey Medical Corporation (NASDAQ: DERM)
CRDL vs DERM Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, DERM has a market cap of 213.8M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while DERM trades at $7.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas DERM's P/E ratio is -21.00. In terms of profitability, CRDL's ROE is -1.94%, compared to DERM's ROE of -0.20%. Regarding short-term risk, CRDL is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check DERM's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
CRDL vs LFCR Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, LFCR has a market cap of 177.8M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while LFCR trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas LFCR's P/E ratio is -4.43. In terms of profitability, CRDL's ROE is -1.94%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, CRDL is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check LFCR's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
CRDL vs REPH Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas REPH's P/E ratio is -8.04. In terms of profitability, CRDL's ROE is -1.94%, compared to REPH's ROE of -0.22%. Regarding short-term risk, CRDL is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check REPH's competition here
Organigram Global Inc. (NASDAQ: OGI)
CRDL vs OGI Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, OGI has a market cap of 167.5M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while OGI trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas OGI's P/E ratio is 2.67. In terms of profitability, CRDL's ROE is -1.94%, compared to OGI's ROE of +0.21%. Regarding short-term risk, CRDL is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check OGI's competition here
Theratechnologies Inc. (NASDAQ: THTX)
CRDL vs THTX Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas THTX's P/E ratio is -28.83. In terms of profitability, CRDL's ROE is -1.94%, compared to THTX's ROE of +0.36%. Regarding short-term risk, CRDL is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
CRDL vs ASRT Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas ASRT's P/E ratio is -7.10. In terms of profitability, CRDL's ROE is -1.94%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, CRDL is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
CRDL vs SCTL Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas SCTL's P/E ratio is -7.86. In terms of profitability, CRDL's ROE is -1.94%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, CRDL is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
CRDL vs BGM Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, BGM has a market cap of 106.5M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while BGM trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas BGM's P/E ratio is -0.96. In terms of profitability, CRDL's ROE is -1.94%, compared to BGM's ROE of -0.05%. Regarding short-term risk, CRDL is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
CRDL vs PROC Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas PROC's P/E ratio is 1.53. In terms of profitability, CRDL's ROE is -1.94%, compared to PROC's ROE of -2.22%. Regarding short-term risk, CRDL is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check PROC's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
CRDL vs CPIX Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, CPIX has a market cap of 97.7M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while CPIX trades at $6.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas CPIX's P/E ratio is -16.30. In terms of profitability, CRDL's ROE is -1.94%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, CRDL is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check CPIX's competition here
OptiNose, Inc. (NASDAQ: OPTN)
CRDL vs OPTN Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas OPTN's P/E ratio is -4.42. In terms of profitability, CRDL's ROE is -1.94%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, CRDL is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
CRDL vs ZOM Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas ZOM's P/E ratio is -1.62. In terms of profitability, CRDL's ROE is -1.94%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, CRDL is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
CRDL vs GRVI Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas GRVI's P/E ratio is 26.05. In terms of profitability, CRDL's ROE is -1.94%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, CRDL is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
CRDL vs ZYBT Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, ZYBT has a market cap of 77.2M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while ZYBT trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas ZYBT's P/E ratio is -7.41. In terms of profitability, CRDL's ROE is -1.94%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, CRDL is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
CRDL vs ZYNE Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, CRDL's ROE is -1.94%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, CRDL is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
CRDL vs SSIC Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas SSIC's P/E ratio is 11.93. In terms of profitability, CRDL's ROE is -1.94%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, CRDL is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check SSIC's competition here
InterCure Ltd. (NASDAQ: INCR)
CRDL vs INCR Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, INCR has a market cap of 64.4M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while INCR trades at $5.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas INCR's P/E ratio is -12.56. In terms of profitability, CRDL's ROE is -1.94%, compared to INCR's ROE of -0.09%. Regarding short-term risk, CRDL is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check INCR's competition here
Talphera, Inc. (NASDAQ: TLPH)
CRDL vs TLPH Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, TLPH has a market cap of 62.3M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while TLPH trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas TLPH's P/E ratio is -3.87. In terms of profitability, CRDL's ROE is -1.94%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, CRDL is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check TLPH's competition here
The Valens Company Inc. (NASDAQ: VLNS)
CRDL vs VLNS Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas VLNS's P/E ratio is -1.03. In terms of profitability, CRDL's ROE is -1.94%, compared to VLNS's ROE of N/A. Regarding short-term risk, CRDL is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
CRDL vs DRRX Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas DRRX's P/E ratio is -4.44. In terms of profitability, CRDL's ROE is -1.94%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, CRDL is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
CRDL vs JUPW Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas JUPW's P/E ratio is -2.41. In terms of profitability, CRDL's ROE is -1.94%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, CRDL is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
CRDL vs QLI Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas QLI's P/E ratio is -4.92. In terms of profitability, CRDL's ROE is -1.94%, compared to QLI's ROE of -0.16%. Regarding short-term risk, CRDL is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check QLI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
CRDL vs CPHI Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, CPHI has a market cap of 34.2M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while CPHI trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas CPHI's P/E ratio is -1.97. In terms of profitability, CRDL's ROE is -1.94%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, CRDL is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check CPHI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
CRDL vs RMTI Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, RMTI has a market cap of 31.9M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while RMTI trades at $8.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas RMTI's P/E ratio is -6.02. In terms of profitability, CRDL's ROE is -1.94%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, CRDL is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
CRDL vs HEXO Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas HEXO's P/E ratio is -0.26. In terms of profitability, CRDL's ROE is -1.94%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, CRDL is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check HEXO's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
CRDL vs TXMD Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, TXMD has a market cap of 26.6M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while TXMD trades at $2.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas TXMD's P/E ratio is 117.17. In terms of profitability, CRDL's ROE is -1.94%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, CRDL is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
CRDL vs AYTU Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, AYTU has a market cap of 24.5M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while AYTU trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas AYTU's P/E ratio is -1.19. In terms of profitability, CRDL's ROE is -1.94%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, CRDL is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check AYTU's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
CRDL vs CYTH Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas CYTH's P/E ratio is -0.80. In terms of profitability, CRDL's ROE is -1.94%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, CRDL is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
CRDL vs EVOK Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas EVOK's P/E ratio is -7.97. In terms of profitability, CRDL's ROE is -1.94%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, CRDL is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
CRDL vs OPTH Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, OPTH has a market cap of 15.6M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while OPTH trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas OPTH's P/E ratio is -17.71. In terms of profitability, CRDL's ROE is -1.94%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, CRDL is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
CRDL vs ACRX Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas ACRX's P/E ratio is -0.31. In terms of profitability, CRDL's ROE is -1.94%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, CRDL is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
CRDL vs CABR Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, CABR has a market cap of 13.3M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while CABR trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas CABR's P/E ratio is -2.61. In terms of profitability, CRDL's ROE is -1.94%, compared to CABR's ROE of -3.86%. Regarding short-term risk, CRDL is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
CRDL vs AGRX Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas AGRX's P/E ratio is -0.89. In terms of profitability, CRDL's ROE is -1.94%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, CRDL is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
CRDL vs NLTX Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas NLTX's P/E ratio is -0.28. In terms of profitability, CRDL's ROE is -1.94%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, CRDL is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
CRDL vs LCI Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas LCI's P/E ratio is -0.04. In terms of profitability, CRDL's ROE is -1.94%, compared to LCI's ROE of +1.66%. Regarding short-term risk, CRDL is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
CRDL vs ADMP Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas ADMP's P/E ratio is -0.08. In terms of profitability, CRDL's ROE is -1.94%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, CRDL is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check ADMP's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
CRDL vs GELS Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, GELS has a market cap of 6.3M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while GELS trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas GELS's P/E ratio is -1.38. In terms of profitability, CRDL's ROE is -1.94%, compared to GELS's ROE of -0.25%. Regarding short-term risk, CRDL is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check GELS's competition here
cbdMD, Inc. (AMEX: YCBD)
CRDL vs YCBD Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, YCBD has a market cap of 5.1M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while YCBD trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas YCBD's P/E ratio is -1.19. In terms of profitability, CRDL's ROE is -1.94%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, CRDL is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check YCBD's competition here
Mallinckrodt plc (AMEX: MNK)
CRDL vs MNK Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas MNK's P/E ratio is -0.44. In terms of profitability, CRDL's ROE is -1.94%, compared to MNK's ROE of -0.36%. Regarding short-term risk, CRDL is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
CRDL vs FLGC Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas FLGC's P/E ratio is -0.19. In terms of profitability, CRDL's ROE is -1.94%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, CRDL is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
CRDL vs UPC Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, UPC has a market cap of 3M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while UPC trades at $4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas UPC's P/E ratio is -0.59. In terms of profitability, CRDL's ROE is -1.94%, compared to UPC's ROE of -0.03%. Regarding short-term risk, CRDL is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
CRDL vs SBFM Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, SBFM has a market cap of 2.8M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while SBFM trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas SBFM's P/E ratio is -0.19. In terms of profitability, CRDL's ROE is -1.94%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, CRDL is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
CRDL vs PLXP Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas PLXP's P/E ratio is -0.22. In terms of profitability, CRDL's ROE is -1.94%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, CRDL is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
CRDL vs ATNX Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas ATNX's P/E ratio is -0.02. In terms of profitability, CRDL's ROE is -1.94%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, CRDL is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check ATNX's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
CRDL vs RDHL Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, RDHL has a market cap of 2.3M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while RDHL trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas RDHL's P/E ratio is 0.15. In terms of profitability, CRDL's ROE is -1.94%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, CRDL is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check RDHL's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
CRDL vs SNOA Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while SNOA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas SNOA's P/E ratio is -1.09. In terms of profitability, CRDL's ROE is -1.94%, compared to SNOA's ROE of -0.46%. Regarding short-term risk, CRDL is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for CRDL.Check SNOA's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
CRDL vs SHPH Comparison September 2026
Cardiol Therapeutics Inc. (NASDAQ: CRDL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDL stands at 250.1M. In comparison, SHPH has a market cap of 2.1M. Regarding current trading prices, CRDL is priced at $2.17 on the NASDAQ, while SHPH trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDL currently has a P/E ratio of -8.65, whereas SHPH's P/E ratio is -0.17. In terms of profitability, CRDL's ROE is -1.94%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, CRDL is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for CRDL.Check SHPH's competition here